{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:45:04Z","timestamp":1787319904501,"version":"build-2736575974"},"reference-count":28,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The bicyclic nucleoside analogue (BCNA) Cf1743 and its orally bioavailable prodrug FV-100 have unique potential as varicella-zoster virus (VZV) inhibitors to treat herpes zoster (shingles) and the therewith associated pain, including post-herpetic neuralgia (PHN). The anti-VZV activity of Cf1743 depends on a specific phosphorylation by the VZV-encoded thymidine kinase (TK). The target of antiviral action is assumed to be the viral DNA polymerase (or DNA synthesis in the virus-infected cells).<\/jats:p>","DOI":"10.3390\/v14040770","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T22:23:23Z","timestamp":1649370203000},"page":"770","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["FV-100 for the Treatment of Varicella-Virus (VZV) Infections: Quo Vadis?"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-8890","authenticated-orcid":false,"given":"Erik","family":"De Clercq","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3851\/IMP1472","article-title":"FV-100: The most potent and selective anti-varicella zoster virus agent reported to date","volume":"20","author":"Migliore","year":"2010","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/med.10035","article-title":"Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues","volume":"23","year":"2003","journal-title":"Med. Res. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Gross, G., and Doerr, H.W. (2006). Highly Potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues (BCNAs). Herpes Zoster, Karger. Recent Aspects of Diagnosis and Control.","DOI":"10.1159\/isbn.978-3-318-01256-9"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1517\/14728214.13.3.393","article-title":"Emerging antiviral drugs","volume":"13","year":"2008","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/med.21281","article-title":"A cutting-edge view on the current state of antiviral drug development","volume":"33","year":"2013","journal-title":"Med. Res. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3851\/IMP2533","article-title":"Selective anti-herpesvirus agents","volume":"23","year":"2013","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.apsb.2015.09.001","article-title":"An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964\u20132014","volume":"5","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/14728214.2011.591786","article-title":"Emerging drugs for varicella-zoster virus infections","volume":"16","author":"Andrei","year":"2011","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/B978-0-12-405880-4.00004-4","article-title":"Advances in the treatment of varicella-zoster virus infections","volume":"67","author":"Andrei","year":"2013","journal-title":"Adv. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Andrei, G., and Snoeck, R. (2021). Advances and perspectives in the management of Varicella-Zoster virus infections. Molecules, 26.","DOI":"10.3390\/molecules26041132"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/clpt.2010.178","article-title":"Update on new antivirals under development for the treatment of double-stranded DNA virus infections","volume":"88","author":"Dropulic","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.coviro.2011.10.015","article-title":"Progress in the development of new therapies for herpesvirus infections","volume":"1","author":"Price","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/QCO.0000000000000211","article-title":"Herpes simplex virus and varicella zoster virus: Recent advances in therapy","volume":"28","author":"De","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1021\/jm990346o","article-title":"Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base","volume":"42","author":"McGuigan","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1021\/jm000210m","article-title":"Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain","volume":"43","author":"McGuigan","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1128\/AAC.49.3.1081-1086.2005","article-title":"Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides","volume":"49","author":"Andrei","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1124\/mol.61.5.1140","article-title":"Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase","volume":"61","author":"Balzarini","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/mol.61.2.249","article-title":"Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase","volume":"61","author":"Sienaert","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/jac\/dkm376","article-title":"Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus","volume":"60","author":"McGuigan","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1128\/AAC.01446-10","article-title":"Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers","volume":"55","author":"Pentikis","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/jmv.24750","article-title":"FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial","volume":"89","author":"Tyring","year":"2017","journal-title":"J. Med. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1023\/B:PHAM.0000029277.60760.43","article-title":"In vitro delivery of novel, highly potent anti-varicella zoster virus nucleoside analogues to their target site in the skin","volume":"21","author":"Jarvis","year":"2004","journal-title":"Pharm. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3851\/IMP1661","article-title":"Evaluation of novel phosphoramidate ProTides of the 2\u2032-fluoro derivatives of a potent anti-varicella zoster virus bicyclic nucleoside analogue","volume":"21","author":"Derudas","year":"2010","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1016\/j.bmcl.2009.09.116","article-title":"2\u2032-Fluorosugar analogues of the highly potent anti-varicella-zoster virus bicyclic nucleoside analogue (BCNA) Cf 1743","volume":"19","author":"McGuigan","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bcp.2017.11.023","article-title":"Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections","volume":"153","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_26","unstructured":"(2022, April 04). ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study. Available online: https:\/\/www.prnewswire.com\/news-releases\/contravir-pharmaceuticals-reports-positive-results-confirming-the-safety-of-its-shingles-candidate-fv-100-in-a-drug-drug-interaction-study-300230016.html."},{"key":"ref_27","unstructured":"(2022, April 04). A Comparative Study of FV-100, vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02412917."},{"key":"ref_28","unstructured":"(2022, April 04). ContraVir Pharmaceuticals Announces Name Change to Hepion Pharmaceuticals, Inc.; Trading Symbol Change to \u201cHEPA\u201d. Available online: https:\/\/www.globenewswire.com\/news-release\/2019\/07\/22\/1885994\/0\/en\/ContraVir-Pharmaceuticals-Announces-Name-Change-to-Hepion-Pharmaceuticals-Inc-Trading-Symbol-Change-to-HEPA.html."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/4\/770\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:50:07Z","timestamp":1760136607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/4\/770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["v14040770"],"URL":"https:\/\/doi.org\/10.3390\/v14040770","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]}}}